Form 4: Castle Biosciences CEO Sells Shares Under 10b5-1 Plan

Castle Biosciences Inc. President and CEO Derek J. Maetzold reported the sale of 19,300 shares of common stock through a pre-arranged 10b5-1 plan.

Summary

• Derek J. Maetzold, President & Chief Executive Officer and a Director of Castle Biosciences Inc. (CSTL), reported the sale of common stock.
• On March 17, 2026, 18,650 shares of common stock were disposed of at a weighted-average price of $25.93 per share, totaling approximately $483,804.50.
• On March 18, 2026, an additional 650 shares of common stock were disposed of at a weighted-average price of $25.39 per share, totaling approximately $16,503.50.
• These transactions were executed pursuant to a Rule 10b5-1 plan adopted by Mr. Maetzold on December 3, 2025.
• Following these transactions, Mr. Maetzold directly beneficially owns 21,479 shares of common stock.
• Indirect beneficial ownership includes 51,566 shares held by The Maetzold Descendants 2020 Trust, 43,826 shares by Derek Maetzold 2020 Irrevocable Trust, 3,336 shares each by four separate Maetzold 2018 Remainder Trusts, 85,959 shares by DJM Grantor Retained Annuity Trust No. 5, 18,718 shares by DJM Grantor Retained Annuity Trust No. 6, and 44,323 shares by DJM Grantor Retained Annuity Trust No. 7.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sales were conducted under a pre-arranged 10b5-1 plan, which typically indicates a planned financial management strategy rather than a reaction to new company-specific news, thus not significantly altering the investment sentiment.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned and systematic approach to managing personal holdings rather than a reaction to new, negative material information.

Negatives

• Insider selling, even under a 10b5-1 plan, reduces the direct equity stake of a key executive in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 plan are a common practice for executives to manage personal finances, diversify portfolios, or address liquidity needs. These pre-arranged plans help mitigate concerns about insider trading based on material non-public information, as the trading parameters are set in advance.

Related Party Transactions

• The reporting person holds indirect beneficial ownership through various trusts, including The Maetzold Descendants 2020 Trust (where the reporting person's spouse is trustee and spouse/children are beneficiaries), Derek Maetzold 2020 Irrevocable Trust (where the reporting person is trustee and children are beneficiaries), and several Maetzold 2018 Remainder Trusts (where the reporting person is trustee and children are beneficiaries).
• Additional indirect holdings are through DJM Grantor Retained Annuity Trust No. 5 (where the reporting person is trustee and beneficiary), DJM Grantor Retained Annuity Trust No. 6 (where the reporting person is trustee and beneficiaries are other trusts for his children), and DJM Grantor Retained Annuity Trust No. 7 (where the reporting person is trustee and beneficiary).

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be perceived as a slight reduction in management's direct alignment with shareholder interests, though the 10b5-1 plan mitigates this concern.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The reported sales by the CEO were conducted under a pre-established Rule 10b5-1 trading plan, indicating a planned diversification or liquidity event rather than a reaction to new material information. This type of transaction generally does not suggest a change in the company's fundamental outlook or warrant an immediate shift in investment strategy, thus a 'hold' recommendation is appropriate.

Keywords

Castle Biosciences, CSTL, insider trading, Form 4, stock sale, CEO, Derek Maetzold, 10b5-1 plan, common stock